Kristin Connarn wrote this bylined article on FDA suggested guidance for labeling biosimilar products. The FDA recommends that in biosimilar product labeling, applicants incorporate relevant data and information from the reference product label, with appropriate product-specific modifications, Ms. Connarn wrote, adding that “it is not required that the text be identical to that of the reference product label.”
Read the full article.
